Clinical Study
Effect of a Selective Progesterone Receptor Modulator on Induction of Apoptosis in Uterine Fibroids In Vivo
Table 1
Baseline parameters of the groups of the study.
| | Type of preoperative treatment | SPRM | GnRHa | No treatment | | (11 patients) | (17 patients) | (10 patients) |
| | Mean age (years) | 36.4 | 33.3 | 37.9 | | Mean BMI (kg/m2) | 24.4 | 23.0 | 22.8 | | Mean diameter of dominant fibroid (mm) | 58.3 | 68.1 | 60.8 | | Mean number of myomas (larger than 10 mm) | 2.5 | 2.3 | 2.6 | | Mean number of deliveries of patients | 0.9 | 0.6 | 0.8 | | Mean interval between last tablet intake/last depot injection and surgery (days) | 7.5 | 35.1 | — |
|
|
BMI: body mass index, GnRHa: gonadoliberin agonist, and SPRM: selective progesterone receptor modulator.
|
